<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

NEWSROOM Press Releases

    254 Results

    Biodesix® Named Innovative Company of the Year at 2016 IQ Awards

    Biodesix won the BizIQ award, 2016 Innovative Company of the Year.

    Biodesix’ VeriStrat Test Now Covered By Humana, Medical Mutual of Ohio, PreferredOne

    Humana, Medical Mutual of Ohio and Preferred One independently determined and published a policy stating that VeriStrat can be considered medically necessary for patients with (NSCLC)

    More Information on Disease State and Trial Options for Patients with Advanced Non-Small Cell Lung Cancer; Evaluating Automated and Manual Workflows in cfDNA Extraction

    Biodesix, in partnership with BioRad and Qiagen, presents data from new studies at AMP.

    Biodesix Presenting Results From Three Studies at SITC Annual Meeting; Oral Poster Presentation, Two Additional Poster Presentations

    Biodesix will present data from three studies at SITC's annual meeting.

    Biodesix® and Bioyong Announce Agreement for Joint Development and Commercialization of VeriStrat® Test in Greater China

    Biodesix and Bioyong announced a $38M deal for development and commercialization of VeriStrat in China.

    Biodesix’s Diagnostic Cortex™ Platform Used in Three Studies Presented at SITC

    The study results indicate that the tests have the potential to offer clinically relevant information that could help physicians selecting immunotherapies for their patients make the best decision

    Clin-TOF Successfully Integrated into VeriStrat® Workflow

    Clin-TOF successfully integrated into VeriStrat® workflow

    Biodesix® Tests Demonstrate Ability to Stratify Patients Treated with Immunotherapy

    Biodesix presents data at the World Lung Conference showing the ability to stratify lung cancer patients treated with immunotherapy

    Genestrat Liquid Biopsy Testing™ Now Includes ROS1 and RET Mutations

    Biodesix's GeneStrat liquid biopsy test now includes ROS1 and RET mutations. The test helps physicians make treatment decisions for cancer patients.

    Biodesix to Present Study Data: Blood-Based Diagnostic Testing for PD-L1

    Biodesix will present data on blood-based diagnostic testing for PD-L1 at ASCO-SITC 2017; ddPCR test measuring mRNA expression from immune and cancer cells